Johnson & Johnson’s Drug Acquired Via Momenta Deal Shows Encouraging Data In Fetal Disorder
Janssen, a unit of Johnson & Johnson (NYSE:JNJ), announced topline results from the proof-of-concept Phase 2 open-label UNITY trial for…
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its ‘Incrementally Positive’
The FDA has accepted for review a marketing application seeking approval for Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc’s (NASDAQ:BIIB) zuranolone for major depressive…
‘NuCana NUC-3373 In Combination With Other Agents In Patients With Advanced Solid Tumors’ – Clinical Trials
https://clinicaltrials.gov/ct2/show/NCT05714553
Aceragen Announces Recommendation Of Data Monitoring Committee In Terra Study
Aceragen, Inc. (NASDAQ:ACGN) a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, today announced the recommendation of its
Radiology Imaging Associates Launches The Enhanced Breast Cancer Detection Program, Providing Women A New State-Of-The-Art Solution Powered By Artificial Intelligence
Radiology Imaging Associates, a division of RadNet, Inc. (NASDAQ:RDNT), today announced that it has started implementation of its new Enhanced Breast Cancer Detection (EBCD) service (https://myEBCDmammo.com), which works
Centessa Pharmaceuticals To Present Additional Data From Open-Label Extension Of Phase 2a Study Of SerpinPC For Hemophilia At The 16th Annual Congress Of The European Association For Haemophilia And Allied Disorders On February 10, 2023
Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the Company will present
Redhill Biopharma Announces Extinguishment Of Its Debt Obligations Under Credit Agreement Between Its U.S. Subsidiary And HCR Dated February 23, 2020, In Exchange For The Transfer Of Its Rights In Movantik To HealthCare Royalty’s (HCR) Affiliate
HCR will assume substantially all post-closing liabilities, and RedHill will retain substantially all pre-closing liabilities relating to Movantik (Naloxegol). HCR will retain security interests in certain RedHill assets
Addex Therapeutics Concludes Enrollment In Part 1 Of Phase 2 Study of ADX71149 For Epilepsy. Independent Interim Review Committee’s Outcome And Next Steps For The Program Are Expected By The End Of Q1 2023
The trial is being conducted by Janssen Pharmaceuticals Inc part of Johnson & Johnson. Based on the outcome of the review and recommendations from the IRC, Janssen will evaluate the next steps for
SpringBig Holdings Tweets ‘We’re Happy To Announce That SpringBig Has Recently Integrated With Pluggi, A Personal AI Budtender That Simplifies Dispensary Shopping With Relevant Product Recommendations Generated In Seconds!’; Shares Halt On Circuit Brea…
https://springbig.com/post/dispensary-ecommerce-ai-budtender/?utm_source=Linkedin&utm_medium=Blog&utm_campaign=Pluggi_integration